Uterine Benign Neoplasm malady

Categories: Cancer diseases

Aliases & Classifications for Uterine Benign Neoplasm

Aliases & Descriptions for Uterine Benign Neoplasm:

Name: Uterine Benign Neoplasm 12 14


External Ids:

Disease Ontology 12 DOID:0060095

Summaries for Uterine Benign Neoplasm

MalaCards based summary : Uterine Benign Neoplasm is related to uterine fibroid and pericardium leiomyoma. An important gene associated with Uterine Benign Neoplasm is HPSE2 (Heparanase 2 (Inactive)), and among its related pathways/superpathways is Thyroid hormone signaling pathway. The drugs Progesterone and Tranexamic Acid have been mentioned in the context of this disorder. Related phenotype is Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435).

Related Diseases for Uterine Benign Neoplasm

Diseases related to Uterine Benign Neoplasm via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 55)
id Related Disease Score Top Affiliating Genes
1 uterine fibroid 11.0
2 pericardium leiomyoma 10.3 MED12 PGR
3 bartholin's gland benign neoplasm 10.3 ESR1 PGR
4 cardiovascular organ benign neoplasm 10.3 ESR1 PGR
5 appendix leiomyoma 10.3 ESR1 PGR
6 bronchus adenoma 10.3 ESR1 PGR
7 glioma 10.3 ESR1 PGR
8 ovarian benign neoplasm 10.3 ESR1 PGR
9 plexiform neurofibroma 10.3 ESR1 PGR
10 paranasal sinus disease 10.3 ESR1 PGR
11 deafness, autosomal recessive 21 10.3 ESR1 PGR
12 cervical lymphoepithelioma-like carcinoma 10.3 ESR1 PGR
13 histiocytic and dendritic cell cancer 10.3 ESR1 PGR
14 atypical lipomatous tumor 10.3 ESR1 PGR
15 congenital disorder of glycosylation, type ic 10.3 ESR1 PGR
16 her2-receptor negative breast cancer 10.3 ESR1 PGR
17 intestinal perforation 10.3 ESR1 PGR
18 perlman syndrome 10.3 ESR1 PGR
19 nervous system hibernoma 10.3 ESR1 PGR
20 bladder adenocarcinoma 10.3 ESR1 PGR
21 anal neuroendocrine tumor 10.3 ESR1 PGR
22 lymphomatous thyroiditis 10.3 PGR TSC2
23 osteogenesis imperfecta 10.3 ESR1 PGR
24 male reproductive organ benign neoplasm 10.2 ESR1 MED12 PGR
25 central nervous system primitive neuroectodermal neoplasm 10.2 ESR1 MED12 PGR
26 poliomyelitis 10.2 ESR1 PGR
27 pilar sheath acanthoma 10.2 ESR1 HMGA2 PGR
28 vulva basal cell carcinoma 10.2 ESR1 PGR
29 multiple mitochondrial dysfunctions syndrome 1 10.2 HMGA2 TSC2
30 polycythemia 10.2 PGR TSC2
31 villoglandular endometrial endometrioid adenocarcinoma 10.2 ESR1 PGR
32 vaginal adenosarcoma 10.2 ESR1 PGR
33 intraneural perineurioma 10.2 ESR1 PGR
34 glycerol kinase deficiency, adult form 10.2 ESR1 PGR TGFB3
35 renal tubular transport disease 10.2 TGFB3 TSC2
36 t-cell adult acute lymphocytic leukemia 10.2 ESR1 PGR TSC2
37 organ system benign neoplasm 10.2 ESR1 PGR TSC2
38 renal clear cell carcinoma 10.2 FH TSC2
39 gangliosidosis gm1 10.2 ESR1 PGR TSC2
40 middle ear adenocarcinoma 10.2 ESR1 PGR
41 acute thyroiditis 10.2 ESR1 PGR
42 nephrogenic adenofibroma 10.2 ESR1 HPSE2 MED12 PGR
43 spinocerebellar ataxia, autosomal recessive 2 10.1 ESR1 PGR TSC2
44 breast duct papilloma 10.1 ESR1 HMGA2 MED12 PGR
45 vestibular gland benign neoplasm 10.1 FH HMGA2 TSC2
46 pediatric intraocular retinoblastoma 10.1 ESR1 IVL PGR
47 ovarian clear cell malignant adenofibroma 10.1 ESR1 IVL PGR
48 paraphimosis 10.1 ESR1 PGR
49 epithelioid neurofibroma 10.1 ESR1 FH MED12 PGR
50 central nervous system mature teratoma 10.0 ESR1 PGR

Graphical network of the top 20 diseases related to Uterine Benign Neoplasm:

Diseases related to Uterine Benign Neoplasm

Symptoms & Phenotypes for Uterine Benign Neoplasm

GenomeRNAi Phenotypes related to Uterine Benign Neoplasm according to GeneCards Suite gene sharing:

id Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased cell death in breast cancer cell lines (MCF10A, MDA-MB-435) GR00104-A-0 8.8 ESR1 FH RAD51B

Drugs & Therapeutics for Uterine Benign Neoplasm

Drugs for Uterine Benign Neoplasm (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 112)
id Name Status Phase Clinical Trials Cas Number PubChem Id
Progesterone Approved, Vet_approved Phase 4,Phase 2 57-83-0 5994
Tranexamic Acid Approved Phase 4 1197-18-8 5526
Leuprolide Approved, Investigational Phase 4 53714-56-0 3911 657181
Nitroglycerin Approved, Investigational Phase 4 55-63-0 4510
Celecoxib Approved, Investigational Phase 4 169590-42-5 2662
Pregabalin Approved, Illicit, Investigational Phase 4 148553-50-8 5486971
7 Coagulants Phase 4,Phase 3
8 Hemostatics Phase 4,Phase 3
9 Central Nervous System Depressants Phase 4
10 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2
11 Antifibrinolytic Agents Phase 4
12 Antineoplastic Agents, Hormonal Phase 4,Phase 2
13 Fertility Agents Phase 4
14 Analgesics Phase 4
15 Analgesics, Non-Narcotic Phase 4
16 Anti-Anxiety Agents Phase 4
17 Anticonvulsants Phase 4
18 Anti-Inflammatory Agents Phase 4
19 Anti-Inflammatory Agents, Non-Steroidal Phase 4
20 Antirheumatic Agents Phase 4
21 calcium channel blockers Phase 4
22 Calcium, Dietary Phase 4
23 Cyclooxygenase 2 Inhibitors Phase 4
24 Cyclooxygenase Inhibitors Phase 4
25 Psychotropic Drugs Phase 4
26 Tranquilizing Agents Phase 4
27 Iron Supplement Nutraceutical Phase 4
Mifepristone Approved, Investigational Phase 3,Phase 1 84371-65-3 55245
Epinephrine Approved, Vet_approved Phase 3 51-43-4 5816
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
Ifosfamide Approved Phase 3 3778-73-2 3690
Lenograstim Approved Phase 3 135968-09-1
Mechlorethamine Approved Phase 3 51-75-2 4033
Simvastatin Approved Phase 3 79902-63-9 54454
Doxil Approved June 1999 Phase 3 31703
36 Hormone Antagonists Phase 3,Phase 2,Phase 1
37 Hormones Phase 3,Phase 2,Phase 1
38 Hormones, Hormone Substitutes, and Hormone Antagonists Phase 3,Phase 2,Phase 1
39 Contraceptive Agents Phase 3,Phase 2,Phase 1
40 Contraceptives, Oral Phase 3,Phase 2,Phase 1
41 Contraceptives, Postcoital Phase 3,Phase 1
42 Luteolytic Agents Phase 3,Phase 1
43 Adrenergic Agents Phase 3
44 Adrenergic Agonists Phase 3
45 Adrenergic alpha-Agonists Phase 3
46 Adrenergic beta-Agonists Phase 3
47 Anti-Asthmatic Agents Phase 3
48 Arginine Vasopressin Phase 3
49 Autonomic Agents Phase 3
50 Bronchodilator Agents Phase 3

Interventional clinical trials:

(show top 50) (show all 61)
id Name Status NCT ID Phase
1 Ulipristal Use in Chinese Population Recruiting NCT02825719 Phase 4
2 Ulipristal Acetate Versus GnRH Analogue Treatment Before Hysteroscopic Resection of Uterine Leiomyoma Recruiting NCT02361879 Phase 4
3 A Comparison of Single Versus Double Evacuation for Treatment of Hydatidiform Mole Recruiting NCT01630954 Phase 4
4 Surgical Success After Laparoscopic vs Abdominal Hysterectomy Recruiting NCT01793584 Phase 4
5 Preemptive Analgesia Following Uterine Artery Embolization Terminated NCT01555073 Phase 4
6 Single-port Access Laparoscopic-assisted Vaginal Hysterectomy Unknown status NCT01048931 Phase 3
7 Trial of Mifepristone for Fibroids Completed NCT00133705 Phase 3
8 Vasopressin Versus Epinephrine in Myomectomy Completed NCT01861015 Phase 3
9 MR Guided Focused Ultrasound Treatment of Uterine Fibroids With Enhanced Sonication Completed NCT00365989 Phase 3
10 Impact of Opportunistic Salpingectomy on Ovarian Reserve in Patients Undergoing Laparoscopic Hysterectomy Completed NCT01893086 Phase 3
11 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3
12 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3
13 The Effect of Simvastatin on Uterine Leiomyoma Development and Growth in Infertile Women Recruiting NCT03134157 Phase 3
14 Study of Volume Reduction of Uterine Fibroids After Embolization or Microwave Treatment Not yet recruiting NCT02942537 Phase 2, Phase 3
15 Treatment of Uterine Fibroids With CDB-2914, an Experimental Selective Progesterone Receptor Antagonist Completed NCT00044876 Phase 2
16 Randomized Pilot Study for the Treatment of Cutaneous Leiomyomas With Botulinum Toxin Completed NCT00971620 Phase 2
17 Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Completed NCT00474994 Phase 2
18 Sorafenib in Treating Patients With Metastatic, Locally Advanced, or Recurrent Sarcoma Completed NCT00245102 Phase 2
19 AZD0530 in Treating Patients With Recurrent Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00659360 Phase 2
20 Megestrol Acetate or Levonorgestrel-Releasing Intrauterine System in Treating Patients With Atypical Endometrial Hyperplasia or Endometrial Cancer Withdrawn NCT01943058 Phase 2
21 The Effect of Mifepristone on Uterine Fibroids and Breast Tissue Completed NCT00579475 Phase 1
22 Aromatase Inhibitors for Treatment of Uterine Leiomyomas Withdrawn NCT00945360 Phase 1
23 The Benefits and Limits of Laparoscopic Surgery for Uterine Fibroids Unknown status NCT00860002
24 Minimally Invasive Benign Hysterectomy Unknown status NCT01865929
25 Linking Obesity and Estrogen-responsive Genes in Endometrial Cancer Unknown status NCT02226302
26 ENDOMET - Novel Diagnostic Tools and Treatments for Endometriosis Unknown status NCT01301885
27 Prospective Evaluation of Lymphoedema Among Patients With Gynaecological Cancer Completed NCT00604994
28 Total Versus Subtotal Abdominal Hysterectomy Completed NCT01880710
29 Comparison of TLH and LAVH With Over Than 500g Completed NCT03146299
30 Postoperative Urinary Retention and Urinary Track Infection (UTI) After Laparoscopic Assisted Vaginal Hysterectomy (LAVH) for Benign Disease Completed NCT00564135
31 Endometrial Polyps: Pathophysiology and Clinical Consequences Completed NCT00247923
32 Preemptive Analgesia for Abdominal Hysterectomy Completed NCT00121498
33 Development and Pilot Test of an Elective Bilateral Salpingo-Oophorectomy (BSO) Decision Support Guide Completed NCT01369654
34 Lavage of the Uterine Cavity for the Diagnosis of Ovarian and Tubal Carcinoma - Study of Sensitivity and Specificity Recruiting NCT02518256
35 Colony-Stimulating Factor-1 (CSF-1) and Other Cytokines in Human Endometrial Carcinogenesis Recruiting NCT00250770
36 Hereditary Leiomyomatosis Renal Cell Cancer - Study of the Genetic Cause and the Predisposition to Renal Cancer Recruiting NCT00050752
37 Tumor Bank for Tissue Samples Recruiting NCT01789229
38 Scientific Protocol for the Study of Thyroid Cancer and Other Thyroid Disease in Belarus Following the Chernobyl Accident Recruiting NCT00339716
39 Prognostic Markers of Gynecologic Cancers Recruiting NCT00290459
40 DOvEEgene: Developing and Validating a Novel Molecular Screening Test for the Early Diagnosis of Cancer of the Endometrium, Tubes and Ovaries Recruiting NCT02288676
41 Biomarkers for Gynecologic Cancer Recruiting NCT02178462
42 Treatment of Benign Uterine Disorders Using High Intensity Focused Ultrasound (MR-HIFU) Recruiting NCT02914704
43 Serum Biomarkers in Diagnosis and Predicting Prognosis of Endometrial and Ovarian Cancers Recruiting NCT03112733
44 Skeletal Muscle Energy Metabolism in Women With Weight Loss and Ovarian and/or Endometrial Cancer With Weight Loss Recruiting NCT03027479
45 Effect of Salpingectomy During Conservative Hysterectomy Recruiting NCT01628432
46 Diagnosis of Cervical Lesions in Women With Unhealthy Looking Cervix Recruiting NCT03150745
47 Rare Disease Patient Registry & Natural History Study - Coordination of Rare Diseases at Sanford Recruiting NCT01793168
48 High-intensity Focused Ultrasound in Treatment of Uterine Fibroid Active, not recruiting NCT02954744
49 Barriers for the Uptake of LaparoScopic Hysterectomy Active, not recruiting NCT02167672
50 Benign Reproductive Tissue Analysis for Endometrial Cancer Markers Active, not recruiting NCT00481754

Search NIH Clinical Center for Uterine Benign Neoplasm

Genetic Tests for Uterine Benign Neoplasm

Anatomical Context for Uterine Benign Neoplasm

Publications for Uterine Benign Neoplasm

Variations for Uterine Benign Neoplasm

Expression for Uterine Benign Neoplasm

Search GEO for disease gene expression data for Uterine Benign Neoplasm.

Pathways for Uterine Benign Neoplasm

Pathways related to Uterine Benign Neoplasm according to GeneCards Suite gene sharing:

id Super pathways Score Top Affiliating Genes
1 10.86 ESR1 MED12 TSC2

GO Terms for Uterine Benign Neoplasm

Biological processes related to Uterine Benign Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 transcription initiation from RNA polymerase II promoter GO:0006367 9.43 ESR1 MED12 PGR
2 intracellular steroid hormone receptor signaling pathway GO:0030518 9.16 ESR1 MED12
3 embryonic neurocranium morphogenesis GO:0048702 8.96 MED12 TGFB3
4 negative regulation of Wnt signaling pathway GO:0030178 8.8 HMGA2 MED12 TSC2

Molecular functions related to Uterine Benign Neoplasm according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 steroid binding GO:0005496 8.62 ESR1 PGR

Sources for Uterine Benign Neoplasm

9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
32 HPO
33 ICD10
34 ICD10 via Orphanet
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
52 Novoseek
55 OMIM via Orphanet
59 PubMed
65 SNOMED-CT via Orphanet
68 Tocris
70 UMLS via Orphanet
Loading form....